Dr. Murai Éva - Gubányi András szerk.: Parasitologia Hungarica 29-30. (Budapest, 1997)

Table 1 Immune status to toxoplasmosis during pregnancy over a nine-year period No. of gravidas Group A Seronegative Group B Seropositive Group C Seroconverted Group D HIAL with Groups C+D (Treated (Groups subjects subjects subjects anti-P30 IgA pos.*** with Spiramycin) A+B) No. % No. % No. %** No. %•*** No. o/

o

***** 1987* 1758 718 40.8 1040 59.2 1 0.14 7 0.67 8 0.45 1988 2199 805 36.6 1394 63.4 1 0.12 4 0.29 5 0.22 1989 2270 890 39.2 1380 60.8 4 0.45 5 0.36 9 0.40 1990 2218 980 44.2 1238 55.8 2 0.20 3 0.24 5 0.23 1991 2491 668 26.8 1823 73.2 0 0 13 0.71 13 0.52 1992 2273 670 29.5 1603 70.5 1 0.15 12 0.74 13 0.57 1993 2299 823 35.8 1476 64.2 0 0 14 0.95 14 0.61 1994 2386 1069 44.8 1317 55.2 1 0.09 20 1.52 21 0.88 1995 2091 889 42.5 1202 57.5 1 0.11 26 2.16 27 1.29 Total: 19985 7512 37.6 12473 62.4 11 0.15 104 0.83 115 0.58 * Study started on 9 February. 1987. ** Percentage of seronegative women seroconverting during pregnancy. •** HIAL with anti-P30 IgA pos.=high initial antibody levels accompanied by anti-P30 IgA antibodies. ••*• Percentage of seropositive patients with HIAL and anti-P30 IgA. *••** Percentage of gravidas with seroconversion and HIAL with anti-P30 IgA.